In this edition:
Lebrikizumab in moderate-to-severe atopic dermatitis
Apremilast in paediatric patients with moderate-to-severe plaque psoriasis
16- vs 8-week guselkumab for psoriasis control in super responders
Cemiplimab for locally advanced basal-cell carcinoma
Desmoglein 3 chimeric autoantibody receptor T cells for pemphigus vulgaris
Dupilumab for itch and skin lesions in prurigo nodularis
Secukinumab in moderate-to-severe hidradenitis suppurativa
Deucravacitinib long-term efficacy in plaque psoriasis
Ritlecitinib for alopecia areata
Deuruxolitinib for moderate-to-severe alopecia areata
Please login below to download this issue (PDF)